FDA approves Novartis' Mayzent for MS

FDA approves Novartis' Mayzent for MS

Source: 
BioCentury
snippet: 

FDA approved Novartis’ Mayzent siponimod to treat adults with relapsing forms of multiple sclerosis, including secondary progressive MS with active disease, relapse-remitting MS and clinically isolated syndrome. Novartis AG (NYSE:NVS; SIX:NOVN) said it plans to launch the second-generation S1PR1 agonist in the U.S. in about one week.